PMC:4159494 / 19549-20647 JSONTXT

Annnotations TAB JSON ListView MergeView

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4159494","sourcedb":"PMC","sourceid":"4159494","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4159494","text":"The financial burden of each representative component of osteosarcopenic obesity is substantial. For instance, in 2008, direct costs of obesity were estimated to total almost 14 billion US dollars [52], with even more capital lost in indirect costs such as absenteeism, disability, and premature mortality [53]. Direct medical expenditure related to sarcopenia was estimated in 2000 to be around 18.5 billion dollars per year [54]. Those with osteoporosis with a concurrent hip fracture may contribute more than 6 billion dollars on health-care costs per year in order to treat the fracture and underlying osteoporosis; those with osteoporosis without a fracture may contribute to 3.79 billion dollars of health-care costs [55], though both of these estimates are conservative compared to an alternative 13.7–20.3 billion-dollar estimate [5]. Cleary, these three conditions substantially augment the direct cost of the US health-care expenditure with extensive presumed indirect costs. A disease state such as osteosarcopenic obesity would therefore prove to be a considerable economic encumbrance.","tracks":[]}